Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03260790 · ClinicalTrials.gov registry record · Phase 4
Pneumococcal Vaccines in Patients With Asthma
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT03260790: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT03260790 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03260790, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
Interventions
- BIOLOGICAL PCV13
- BIOLOGICAL PPSV23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2020-12-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03260790
The ClinicalTrials.gov registry entry for NCT03260790 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PCV13 is the first listed.
NCT03260790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03260790 about?
NCT03260790 is a clinical study titled "Pneumococcal Vaccines in Patients With Asthma". Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
What is the current status of trial NCT03260790?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2017-10-01. Estimated completion is 2020-12-25.
What interventions are being tested in trial NCT03260790?
The interventions under investigation include: PCV13 (BIOLOGICAL), PPSV23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03260790?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.